Interstitial Pneumonitis-A Newly Recognized Consequence of Intravesical Gemcitabine Therapy

Authors

Venkata Satish Pendela, Rochester Regional HealthFollow
Bassil Said, Rochester Regional HealthFollow
Pujitha Kudaravalli, Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY.
Mamta Chhabria, Rochester Regional HealthFollow
Dharmini Manogna, Rochester Regional HealthFollow
Michael Gurell, Rochester Regional HealthFollow

Department

Internal Medicine

Document Type

Article

Publication Title

American Journal of Therapeutics

First Page

e752

Last Page

e754

DOI

10.1097/MJT.0000000000001206

Volume

29

Issue

6

Publication Date

11-2022

Comments

Record updated with published article citation 2022-11-22 LB.

Published online ahead of print 2020-06-02.

PubMed ID

32516143

Recommended Citation

Pendela, V. S., Said, B., Kudaravalli, P., Chhabria, M., Manogna, D., & Gurell, M. (2022). Interstitial Pneumonitis-A Newly Recognized Consequence of Intravesical Gemcitabine Therapy. American Journal of Therapeutics, 29 (6), e752-e754. https://doi.org/10.1097/MJT.0000000000001206